<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD05290000_2</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P55055</UniProt_ID>
  <Seq_Length>460</Seq_Length>
  <Molecule_Weight>50974</Molecule_Weight>
  <KEGG_ID>hsa:7376</KEGG_ID>
  <Orthology_ID>K08535</Orthology_ID>
  <EBI_ID>EBI-745354</EBI_ID>
  <Function_Summary>Orphan receptor. Binds preferentially to double-stranded oligonucleotide direct repeats having the consensus half-site sequence 5'-AGGTCA-3' and 4-nt spacing (DR-4). Regulates cholesterol uptake through MYLIP-dependent ubiquitination of LDLR, VLDLR and LRP8 (By similarity).</Function_Summary>
  <Pfam_ID>PF00104:Hormone_recep@@PF00105:zf-C4</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Ubiquitously-expressed nuclear receptor</Alias>
      <Alias>Liver X receptor beta</Alias>
      <Alias>Nuclear receptor subfamily 1 group H member 2</Alias>
      <Alias>Nuclear receptor NER</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>A ligand-dependent receptor found in the nucleus of the cell.</Detail>
      <Keyword>Ligand-dependent nuclear receptor activity</Keyword>
      <Ontology_ID>GO:0004879</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with a steroid hormone to initiate a change in cell activity.</Detail>
      <Keyword>Steroid hormone receptor activity</Keyword>
      <Ontology_ID>GO:0003707</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA e.g. promotor binding or rDNA binding.</Detail>
      <Keyword>Sequence-specific DNA binding</Keyword>
      <Ontology_ID>GO:0043565</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>2</Position>
      <Original>Ser</Original>
      <Variation>Phe</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-dependent transcription.</Detail>
      <Keyword>Negative regulation of transcription, DNA-dependent</Keyword>
      <Ontology_ID>GO:0045892</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of pinocytosis. Pinocytosis is the process in which cells take in liquid material from their external environment; literally 'cell drinking'. Liquid is enclosed in vesicles, formed by invagination of the plasma membrane. These vesicles then move into the cell and pass their contents to endosomes.</Detail>
      <Keyword>Negative regulation of pinocytosis</Keyword>
      <Ontology_ID>GO:0048550</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of transcription from the RNA polymerase II promoter.</Detail>
      <Keyword>Positive regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0045944</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency or extent of the series of molecular events generated as a consequence of interferon-gamma binding to a cell surface receptor.</Detail>
      <Keyword>Negative regulation of interferon-gamma-mediated signaling pathway</Keyword>
      <Ontology_ID>GO:0060336</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the frequency, rate or extent of cholesterol efflux. Cholesterol efflux is the directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle.</Detail>
      <Keyword>Positive regulation of cholesterol efflux</Keyword>
      <Ontology_ID>GO:0010875</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate or extent of cholesterol storage. Cholesterol storage is the accumulation and maintenance in cells or tissues of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.</Detail>
      <Keyword>Negative regulation of cholesterol storage</Keyword>
      <Ontology_ID>GO:0010887</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.</Detail>
      <Keyword>Negative regulation of lipid transport</Keyword>
      <Ontology_ID>GO:0032369</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the activity of the enzyme lipoprotein lipase.</Detail>
      <Keyword>Positive regulation of lipoprotein lipase activity</Keyword>
      <Ontology_ID>GO:0051006</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.</Detail>
      <Keyword>Negative regulation of macrophage derived foam cell differentiation</Keyword>
      <Ontology_ID>GO:0010745</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of fatty acids.</Detail>
      <Keyword>Positive regulation of fatty acid biosynthetic process</Keyword>
      <Ontology_ID>GO:0045723</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate, frequency, or extent of triglyceride biosynthesis. Triglyceride biosynthesis is the collection of chemical reactions and pathways resulting in the formation of triglyceride, any triester of glycerol.</Detail>
      <Keyword>Positive regulation of triglyceride biosynthetic process</Keyword>
      <Ontology_ID>GO:0010867</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the assembly of the RNA polymerase II preinitiation complex (PIC) at an RNA polymerase II promoter region of a DNA template, resulting in the subsequent synthesis of RNA from that promoter. The initiation phase includes PIC assembly and the formation of the first few bonds in the RNA chain, including abortive initiation, which occurs when the first few nucleotides are repeatedly synthesized and then released. Promoter clearance, or release, is the transition between the initiation and elongation phases of transcription.</Detail>
      <Keyword>Transcription initiation from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0006367</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving a protein, occurring at the level of an individual cell.</Detail>
      <Keyword>Positive regulation of cellular protein metabolic process</Keyword>
      <Ontology_ID>GO:0032270</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MSSPTTSSLDTPLPGNGPPQPGAPSSSPTVKEEGPEPWPGGPDPDVPGTDEASSACSTDWVIPDPEEEPERKRKKGPAPKMLGHELCRVCGDKASGFHYNVLSCEGCKGFFRRSVVRGGARRYACRGGGTCQMDAFMRRKCQQCRLRKCKEAGMREQCVLSEEQIRKKKIRKQQQESQSQSQSPVGPQGSSSSASGPGASPGGSEAGSQGSGEGEGVQLTAAQELMIQQLVAAQLQCNKRSFSDQPKVTPWPLGADPQSRDARQQRFAHFTELAIISVQEIVDFAKQVPGFLQLGREDQIALLKASTIEIMLLETARRYNHETECITFLKDFTYSKDDFHRAGLQVEFINPIFEFSRAMRRLGLDDAEYALLIAINIFSADRPNVQEPGRVEALQQPYVEALLSYTRIKRPQDQLRFPRMLMKLVSLRTLSSVHSEQVFALRLQDKKLPPLLSEIWDVHE</Protein_Seq>
    <DNA_Seq>TCGTCAAGTTTCACGCTCCGCCCCTCTTCCGGACGTGACGCAAGGGCGGGGTTGCCGGAAGAAGTGGCGAAGTTACTTTTGAGGGTATTTGAGTAGCGGCGGTGTGTCAGGGGCTAAAGAGGAGGACGAAGAAAAGCAGAGCAAGGGAACCCAGGGCAACAGGAGTAGTTCACTCCGCGAGAGGCCGTCCACGAGACCCCCGCGCGCAGCCATGAGCCCCGCCCCCCGCTGTTGCTTGGAGAGGGGCGGGACCTGGAGAGAGGCTGCTCCGTGACCCCACCATGTCCTCTCCTACCACGAGTTCCCTGGATACCCCCCTGCCTGGAAATGGCCCCCCTCAGCCTGGCGCCCCTTCTTCTTCACCCACTGTAAAGGAGGAGGGTCCGGAGCCGTGGCCCGGGGGTCCGGACCCTGATGTCCCAGGCACTGATGAGGCCAGCTCAGCCTGCAGCACAGACTGGGGCGTCCTTTCTGAAGAACAGATCCGGAAGAAGAAGATTCGGAAACAACAGCAGCAGGAGTCACAGTCACAGTCGCAGTCACCTGTGGGGCCGCAGGGCAGCAGCAGCTCAGCCTCTGGGCCTGGGGCTTCCCCTGGTGGATCTGAGGCAGGCAGCCAGGGCTCCGGGGAAGGCGAGGGTGTCCAGCTAACAGCGGCTCAAGAACTAATGATCCAGCAGTTGGTGGCGGCCCAACTGCAGTGCAACAAACGCTCCTTCTCCGACCAGCCCAAAGTCACGCCCTGGCCCCTGGGCGCAGACCCCCAGTCCCGAGATGCCCGCCAGCAACGCTTTGCCCACTTCACGGAGCTGGCCATCATCTCAGTCCAGGAGATCGTGGACTTCGCTAAGCAAGTGCCTGGTTTCCTGCAGCTGGGCCGGGAGGACCAGATCGCCCTCCTGAAGGCATCCACTATCGAGATCATGCTGCTAGAGACAGCCAGGCGCTACAACCACGAGACAGAGTGTATCACCTTCTTGAAGGACTTCACCTACAGCAAGGACGACTTCCACCGTGCAGGCCTGCAGGTGGAGTTCATCAACCCCATCTTCGAGTTCTCGCGGGCCATGCGGCGGCTGGGCCTGGACGACGCTGAGTACGCCCTGCTCATCGCCATCAACATCTTCTCGGCCGACCGGCCCAACGTGCAGGAGCCGGGCCGCGTGGAGGCGTTGCAGCAGCCCTACGTGGAGGCGCTGCTGTCCTACACGCGCATCAAGAGGCCGCAGGACCAGCTGCGCTTCCCGCGCATGCTCATGAAGCTGGTGAGCCTGCGCACGCTGAGCTCTGTGCACTCGGAGCAGGTCTTCGCCTTGCGGCTCCAGGACAAGAAGCTGCCGCCTCTGCTGTCGGAGATCTGGGACGTCCACGAGTGAGGGGCTGGCCACCCAGCCCCACAGCCTTGCCTGACCACCCTCCAGCAGATAGACGCCGGCACCCCTTCCTCTTCCTAGGGTGGAAGGGGCCCTGGGCCGAGCCTGTAGACCTATCGGCTCTCATCCCTTGGGATAAGCCCCAGTCCAGGTCCAGGAGGCTCCCTCCCTGCCCAGCGAGTCTTCCAGAAGGGGTGAAAGGGTTGCAGGTCCCGACCACTGACCCTTCCCGGCTGCCCTCCCTCCCCAGCTTACACCTCAAGCCCAGCACGCAGTGCACCTTGAACAGAGGGAGGGGAGGACCCATGGCTCTCCCCCCTAGCCCGGGAGACCAGGGCCTTCCTCTTCCTCTGCTTTTATTTAATAAAAACTAAAAACAGAAACAGGAAAATAAAATATGAATACAATCCAGCCCGGAGCTGGAGTGCA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Widely expressed</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleoplasm</CellLocal>
      <Ontology_ID>GO:0005654</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>NR1H2</Gene_Name>
    <Gene_Alias>LXRB; NER; UNR</Gene_Alias>
    <Gene_ID>7376</Gene_ID>
    <Genbank_ACCN>NM_001256647</Genbank_ACCN>
    <Protein_ACCN>NP_001243576</Protein_ACCN>
    <HGNC_ID>7965</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/7376</Gene_URL>
    <EMBL_ID>ENSG00000131408</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>Q99750</Uniprot_ID>
      <Gene_Name>MDFI</Gene_Name>
      <EBI_ID>EBI-724076</EBI_ID>
      <PPI_EBI_URL>EBI-745354,EBI-724076</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Seborrheic Keratosis</Disease_Name>
      <Disease_Detail>Seborrheic Keratosis</Disease_Detail>
      <Disease_DB>SBR005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/seborrheic_keratosis?search=NR1H2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cerebrotendinous Xanthomatosis</Disease_Name>
      <Disease_Detail>Cerebrotendinous Xanthomatosis</Disease_Detail>
      <Disease_DB>CRB011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cerebrotendinous_xanthomatosis?search=NR1H2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Biliary Tract Disease</Disease_Name>
      <Disease_Detail>Biliary Tract Disease</Disease_Detail>
      <Disease_DB>BLR006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/biliary_tract_disease?search=NR1H2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Atherosclerosis</Disease_Name>
      <Disease_Detail>Atherosclerosis</Disease_Detail>
      <Disease_DB>ATH003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/atherosclerosis?search=NR1H2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Complete Androgen Insensitivity Syndrome</Disease_Name>
      <Disease_Detail>Complete Androgen Insensitivity Syndrome</Disease_Detail>
      <Disease_DB>CMP034</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/complete_androgen_insensitivity_syndrome?search=NR1H2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Androgen Insensitivity Syndrome</Disease_Name>
      <Disease_Detail>Androgen Insensitivity Syndrome</Disease_Detail>
      <Disease_DB>AND002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/androgen_insensitivity_syndrome?search=NR1H2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer?search=NR1H2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thyroid Hormone Resistance Syndrome</Disease_Name>
      <Disease_Detail>Thyroid Hormone Resistance Syndrome</Disease_Detail>
      <Disease_DB>THY019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thyroid_hormone_resistance_syndrome?search=NR1H2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dosage-Sensitive Sex Reversal</Disease_Name>
      <Disease_Detail>Dosage-Sensitive Sex Reversal</Disease_Detail>
      <Disease_DB>DSG001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dosage_sensitive_sex_reversal?search=NR1H2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acth-Secreting Pituitary Adenoma</Disease_Name>
      <Disease_Detail>Acth-Secreting Pituitary Adenoma</Disease_Detail>
      <Disease_DB>ACT010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acth_secreting_pituitary_adenoma?search=NR1H2#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS040</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer?search=NR1H2#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317 COMPLEX</PDB_Title>
      <PDB_ID>1PQ9</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1PQ9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands.</PubMed_Title>
      <Author>Farnegardh, M., et al.</Author>
      <Journal>J.Biol.Chem.(2003)278:38821-38828</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12819202?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN LXR BETA HORMONE RECEPTOR / GW3965 COMPLEX</PDB_Title>
      <PDB_ID>1PQ6</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1PQ6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands.</PubMed_Title>
      <Author>Farnegardh, M., et al.</Author>
      <Journal>J.Biol.Chem.(2003)278:38821-38828</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12819202?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-Ray Crystal Structure of LXR Ligand Binding Domain with 24(S),25-epoxycholesterol</PDB_Title>
      <PDB_ID>1P8D</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1P8D</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch.</PubMed_Title>
      <Author>Williams, S., et al.</Author>
      <Journal>J.Biol.Chem.(2003)278:27138-27143</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12736258?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE HUMAN LIVER X RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST</PDB_Title>
      <PDB_ID>1UPW</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1UPW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of the Human Liver X Receptor Beta Ligand-Binding Domain in Complex with a Synthetic Agonist</PubMed_Title>
      <Author>Hoerer, S., et al.</Author>
      <Journal>J.Mol.Biol.(2003)334:853</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14643652?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of LXR ligand binding domain in complex with partial agonist 5</PDB_Title>
      <PDB_ID>4DK8</PDB_ID>
      <Resolution>2.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4DK8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of a new binding mode for a series of liver X receptor agonists.</PubMed_Title>
      <Author>Kopecky, D.J., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2012)22:2407-2410</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22406115?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317</PDB_Title>
      <PDB_ID>1PQC</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1PQC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands.</PubMed_Title>
      <Author>Farnegardh, M., et al.</Author>
      <Journal>J.Biol.Chem.(2003)278:38821-38828</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12819202?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Complex Structure of LXR with an agonist</PDB_Title>
      <PDB_ID>3KFC</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KFC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists.</PubMed_Title>
      <Author>Bernotas, R.C., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:209-212</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19932617?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE HUMAN LIVER X RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST</PDB_Title>
      <PDB_ID>1UPV</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1UPV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of the Human Liver X Receptor Beta Ligand-Binding Domain in Complex with a Synthetic Agonist</PubMed_Title>
      <Author>Hoerer, S., et al.</Author>
      <Journal>J.Mol.Biol.(2003)334:853-861</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14643652?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of LXR ligand binding domain in complex with full agonist 1</PDB_Title>
      <PDB_ID>4DK7</PDB_ID>
      <Resolution>2.45</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4DK7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of a new binding mode for a series of liver X receptor agonists.</PubMed_Title>
      <Author>Kopecky, D.J., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2012)22:2407-2410</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22406115?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray crystal structure of a Potent Liver X Receptor Modulator</PDB_Title>
      <PDB_ID>3L0E</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3L0E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of tertiary sulfonamides as potent liver X receptor antagonists.</PubMed_Title>
      <Author>Zuercher, W.J., et al.</Author>
      <Journal>J.Med.Chem.(2010)53:3412-3416</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20345102?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko03320</Pathway_ID>
      <Pathway_Title>PPAR signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04932</Pathway_ID>
      <Pathway_Title>Non-alcoholic fatty liver disease (NAFLD)</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05160</Pathway_ID>
      <Pathway_Title>Hepatitis C</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.cdh.b.b.dd.html</SCOP_URL>
    <CATH_Class>Class 1: Mainly Alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1p8d</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Type>Protein-induced</Site_Type>
    </AllostericSite>
  </AllostericSite_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>